Feasibility of radical cardiac-sparing, treatment planning strategies for patients with locally advanced, non-small cell lung cancer.
NSCLC
cardiac
treatment planning
Journal
Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
revised:
20
06
2022
received:
07
02
2022
accepted:
21
08
2022
pubmed:
15
10
2022
medline:
31
12
2022
entrez:
14
10
2022
Statut:
ppublish
Résumé
A set of treatment planning strategies were designed and retrospectively implemented for locally advanced, non-small cell lung cancer (NSCLC) patients in order to minimize cardiac dose without compromising target coverage goals. Retrospective analysis was performed for 20 NSCLC patients prescribed to 60-66 Gy that received a mean heart dose (MHD) ≥10 Gy. Three planning approaches were designed and implemented. The first was a multi-isocentric (MI) volume-modulated arc therapy (VMAT) approach (HEART_MI) with one isocenter located within the tumor and the second chosen up to 10 cm away longitudinally. The second was a noncoplanar (NCP) VMAT approach (HEART_NCP) utilizing up to three large couch angles and a standard arc at couch 0. The final planning strategy took a mixed approach (HEART_HYBRID) utilizing the HEART_NCP strategy for two thirds of the treatment combined with a plan utilizing a pair of opposite-opposed gantry angles for the remaining treatments. Investigational plans were compared to original plans using dose-volume histogram metrics such as organ volume receiving greater than x Gy (Vx) or mean dose (Dmean). Although there was a small but statistically significant decrease in internal target volume coverage for HEART_MI plans and, conversely, a statistically significant increase for HEART_NCP plans, all generated plans met physician-prescribed target constraints. For heart dose, there were statistically significant decreases in all heart metrics and particularly MHD for the HEART_MI (9.8 vs. 15.4 Gy [p < 0.001], respectively), HEART_NCP (9.2 vs. 15.4 Gy [p < 0.001]), respectively), and HEART_HYBRID (7.9 vs. 15.4 Gy [p < 0.001], respectively) strategies. The strategy providing the best compromise between plan quality and cardiac dose reduction was HEART_NCP, which produced MHD reductions of 37.6% ± 12.9% (6.2 ± 3.4 Gy) relative to original plans. This strategy could potentially reduce adverse cardiac events, leading to improved quality of life for these patients.
Identifiants
pubmed: 36237114
doi: 10.1002/acm2.13784
pmc: PMC9797161
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13784Informations de copyright
© 2022 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine.
Références
Semin Radiat Oncol. 2021 Apr;31(2):112-119
pubmed: 33610267
Blood. 2017 Apr 20;129(16):2257-2265
pubmed: 28143884
J Radiat Res. 2020 Mar 23;61(2):298-306
pubmed: 32052040
Radiol Oncol. 2018 Feb 21;52(3):281-288
pubmed: 30210037
J Am Coll Cardiol. 2019 Jun 18;73(23):2976-2987
pubmed: 31196455
J Appl Clin Med Phys. 2022 Dec;23(12):e13784
pubmed: 36237114
Sci Rep. 2019 Oct 30;9(1):15671
pubmed: 31666647
JAMA Oncol. 2016 Mar;2(3):359-67
pubmed: 26606200
Medicine (Baltimore). 2020 Sep 18;99(38):e21964
pubmed: 32957314
N Engl J Med. 2013 Mar 14;368(11):987-98
pubmed: 23484825
J Neurosurg. 2000 Dec;93 Suppl 3:219-22
pubmed: 11143252
Ann Oncol. 2017 May 1;28(5):1084-1089
pubmed: 28453703
Phys Med Biol. 2017 Jul 06;62(15):5926-5944
pubmed: 28486217
J Thorac Oncol. 2017 Feb;12(2):293-301
pubmed: 27743888
Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):582-589
pubmed: 30630029
Strahlenther Onkol. 2019 Oct;195(10):861-871
pubmed: 31321461
Support Care Cancer. 2016 Aug;24(8):3669-76
pubmed: 27260018
Pract Radiat Oncol. 2015 May-Jun;5(3):141-148
pubmed: 25957184
J Clin Oncol. 2017 Apr 10;35(11):1171-1178
pubmed: 28095159
Pract Radiat Oncol. 2020 May - Jun;10(3):e147-e154
pubmed: 31586483
J Thorac Oncol. 2018 Oct;13(10):1508-1518
pubmed: 29883836
Int J Radiat Oncol Biol Phys. 2022 Mar 15;112(4):996-1003
pubmed: 34774998
J Clin Oncol. 2017 May 1;35(13):1387-1394
pubmed: 28113017
J Clin Oncol. 2017 May 1;35(13):1395-1402
pubmed: 28301264
J Clin Oncol. 2020 Mar 1;38(7):706-714
pubmed: 31841363
Lung. 2020 Dec;198(6):897-907
pubmed: 33175991
Lancet Oncol. 2015 Feb;16(2):187-99
pubmed: 25601342